| Indiana University Health La Porte Physicians Inc | |
|
1007 Lincolnway La Porte IN 46350-3201 | |
| (219) 326-2489 | |
| (219) 326-2584 |
| Full Name | Indiana University Health La Porte Physicians Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1007 Lincolnway, La Porte, Indiana |
| Authorized Official Name and Position | Brian Donnelly (VP OF STRATEGY & AMBULATORY SERVICE) |
| Authorized Official Contact | 2193254682 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Indiana University Health La Porte Physicians Inc Po Box 1690 La Porte IN 46352-1690 Ph: (219) 326-2312 | Indiana University Health La Porte Physicians Inc 1007 Lincolnway La Porte IN 46350-3201 Ph: (219) 326-2489 |
| NPI Number | 1760593776 |
|---|---|
| Provider Enumeration Date | 08/31/2006 |
| Last Update Date | 05/22/2014 |
| Medicare PECOS PAC ID | 0345147963 |
|---|---|
| Medicare Enrollment ID | O20031212000670 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760593776 | NPI | - | NPPES |
| 200255890 | Medicaid | IN | |
| 100165070 | Medicaid | IN | |
| 200988350 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Primary |
| Provider Name | Elizabeth L Hale |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871598243 PECOS PAC ID: 5799676375 Enrollment ID: I20040323000859 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Jennifer R Frasure |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134213168 PECOS PAC ID: 2769468412 Enrollment ID: I20040624001644 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Nancy J Paunicka |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841287299 PECOS PAC ID: 4183696560 Enrollment ID: I20040806000723 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Franklin Firestone |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164492245 PECOS PAC ID: 8729050158 Enrollment ID: I20040806001058 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Abul W Basher |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1891784500 PECOS PAC ID: 8729054341 Enrollment ID: I20040906000036 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Douglas J. Vanputten |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1851378558 PECOS PAC ID: 4688642796 Enrollment ID: I20040922000938 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Neil W Wangstrom |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1730189820 PECOS PAC ID: 2062474414 Enrollment ID: I20041028000846 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Vinay Chakravarthy Tumuluri |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528015344 PECOS PAC ID: 5496717431 Enrollment ID: I20041101001170 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Thomas M Browne |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548277288 PECOS PAC ID: 0547224149 Enrollment ID: I20041115000005 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Christopher David Sayers |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578677191 PECOS PAC ID: 3779508668 Enrollment ID: I20051010000936 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Maureen Ann Panares |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558461301 PECOS PAC ID: 8426078585 Enrollment ID: I20051205000101 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Julius R Ellis |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1194734145 PECOS PAC ID: 8527097773 Enrollment ID: I20051207001083 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Benjamin C Mannix |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1942235346 PECOS PAC ID: 1951362961 Enrollment ID: I20060425000436 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Kimberly K Pflughaupt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447357199 PECOS PAC ID: 5991800526 Enrollment ID: I20070410000460 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Curtis M Bejes |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730272857 PECOS PAC ID: 5890893481 Enrollment ID: I20070605000472 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | David J Gorecki |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1316923444 PECOS PAC ID: 1052412582 Enrollment ID: I20070727000002 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Diane K Hunt |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801808100 PECOS PAC ID: 1658464276 Enrollment ID: I20070912000338 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Usama Moustafa Moustafa |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1447439922 PECOS PAC ID: 8022108786 Enrollment ID: I20071218000384 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Mckindra Fletcher |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1467448019 PECOS PAC ID: 5395657605 Enrollment ID: I20080102000340 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Jason P Palmateer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083695332 PECOS PAC ID: 9335225853 Enrollment ID: I20080325000269 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Michael J Best |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1083621510 PECOS PAC ID: 1052487337 Enrollment ID: I20080910000639 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Jessica L Nichols |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1972776292 PECOS PAC ID: 7012084627 Enrollment ID: I20080924000239 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | James C Pickford |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1790713733 PECOS PAC ID: 3274600721 Enrollment ID: I20080924000630 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Roman O Filipowicz |
|---|---|
| Provider Type | Practitioner - Neurosurgery |
| Provider Identifiers | NPI Number: 1710989777 PECOS PAC ID: 2961550132 Enrollment ID: I20090427000384 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Michael J Beach |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942219878 PECOS PAC ID: 4183779994 Enrollment ID: I20090831000513 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Gary H Wheeland |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457312357 PECOS PAC ID: 9436293420 Enrollment ID: I20100215000008 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Wayne E Moore |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1003824004 PECOS PAC ID: 4082778436 Enrollment ID: I20100915000884 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Kimberly A Minich |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043525595 PECOS PAC ID: 1759560675 Enrollment ID: I20110125000500 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Jessie B Batchelor |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1609184621 PECOS PAC ID: 1850578352 Enrollment ID: I20110609000747 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Nabil Abdo |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629226089 PECOS PAC ID: 1759551419 Enrollment ID: I20110907001145 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Syed M. Shan-ul-islam |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1487742896 PECOS PAC ID: 2769587948 Enrollment ID: I20110929000480 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Sara L Gonzalez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083996763 PECOS PAC ID: 9931368040 Enrollment ID: I20120309000023 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Jennifer K Vanmeter |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1982978763 PECOS PAC ID: 9032373998 Enrollment ID: I20120606000230 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Melissa L Wilson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831422518 PECOS PAC ID: 2961667282 Enrollment ID: I20120711000229 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Seth F Tatel |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1144433467 PECOS PAC ID: 8426214875 Enrollment ID: I20120730000491 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Ali Esmaili |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1760684013 PECOS PAC ID: 5294927976 Enrollment ID: I20121023000127 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Sandra Renee Gates Manna |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124396072 PECOS PAC ID: 0749431203 Enrollment ID: I20121108000643 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Alexander C Igolnikov |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1437249182 PECOS PAC ID: 4183622913 Enrollment ID: I20121110000067 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Ted George Ody Achufusi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033353792 PECOS PAC ID: 2163673617 Enrollment ID: I20121110000201 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Kimberley K Mendez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043555394 PECOS PAC ID: 7012161946 Enrollment ID: I20130131000189 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Wendy R Dutcher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194077644 PECOS PAC ID: 1658519814 Enrollment ID: I20130529000578 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Andrea Mcgaw |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558704445 PECOS PAC ID: 4183867849 Enrollment ID: I20130827000920 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Shesha Katakam |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1578720439 PECOS PAC ID: 2365519626 Enrollment ID: I20131206001385 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Tracy E Blanton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508290289 PECOS PAC ID: 8325277494 Enrollment ID: I20140213000104 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Janice M Bohlim |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821499328 PECOS PAC ID: 1951623180 Enrollment ID: I20141125001592 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Eddie P Kemper |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1932170602 PECOS PAC ID: 3072511542 Enrollment ID: I20141230000300 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Christina M Matoski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639567761 PECOS PAC ID: 2769706928 Enrollment ID: I20150115002365 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Glorious L Wilson-reynolds |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376898320 PECOS PAC ID: 7315261302 Enrollment ID: I20150122001187 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Praveen Singh |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1760746531 PECOS PAC ID: 3870805062 Enrollment ID: I20150630002587 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Hadeily Salazar Hernandez |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1033463708 PECOS PAC ID: 0446562243 Enrollment ID: I20150708001294 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Alexis Dunlap |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588051726 PECOS PAC ID: 8628381431 Enrollment ID: I20150723007188 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Pooja S Patel |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1881985463 PECOS PAC ID: 0749595262 Enrollment ID: I20150812009084 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Ashley K Kirkwood |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1518214618 PECOS PAC ID: 1355656455 Enrollment ID: I20150819007054 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Rebecca E Waugh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962888677 PECOS PAC ID: 7113233990 Enrollment ID: I20150825005093 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Sonam M Chouksey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720375827 PECOS PAC ID: 3971724915 Enrollment ID: I20150921000518 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
| Provider Name | Sylvia Oudhuis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265899835 PECOS PAC ID: 5890090526 Enrollment ID: I20160218000116 |
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
News Archive
A new study shows significant differences in brain development in high-risk infants who develop autism starting as early as age 6 months. The findings published in the American Journal of Psychiatry reveal that this abnormal brain development may be detected before the appearance of autism symptoms in an infant's first year of life. Autism is typically diagnosed around the age of 2 or 3.
AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to introduce its UV-Blue Light Converters Screens which can quickly and simply change harmful UV into blue light.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
› Verified 1 days ago
Gregory A. Andrews, M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 901 Lincolnway, Suite 206, La Porte, IN 46350 Phone: 219-324-3053 Fax: 219-324-5352 | |
Northshore Health Centers, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 504 Legacy Plz W, La Porte, IN 46350 Phone: 219-763-8112 Fax: 219-764-5333 | |
Community Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 400 Teegarden St, La Porte, IN 46350 Phone: 219-326-0043 | |
Charles F Motley Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 6916 W Johnson Rd, La Porte, IN 46350 Phone: 219-872-7247 Fax: 219-879-8609 | |
Healthlinc, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 400 Teegarden St, La Porte, IN 46350 Phone: 888-580-1060 Fax: 219-465-9507 | |
Laporte Osteopathic Family Practice Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 125 East Shore Parkway, Suite D, La Porte, IN 46350 Phone: 219-325-0155 | |
La Porte Clinic Company Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1331 State St, La Porte, IN 46350 Phone: 219-344-6450 |